Pure Global

Single Dose Escalation Study of CM383 in Healthy Volunteers - Trial NCT06412185

Access comprehensive clinical trial information for NCT06412185 through Pure Global AI's free database. This Phase 1 trial is sponsored by Keymed Biosciences Co.Ltd and is currently Not yet recruiting. The study focuses on Alzheimer Disease. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06412185
Phase 1
Not yet recruiting
biological
Trial Details
ClinicalTrials.gov • NCT06412185
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Single Dose Escalation Study of CM383 in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Dose Escalation of CM383 in Male Healthy Subjects

Study Focus

Alzheimer Disease

CM383

Interventional

biological

Sponsor & Location

Keymed Biosciences Co.Ltd

Timeline & Enrollment

Phase 1

Jun 30, 2024

Jun 30, 2025

44 participants

Primary Outcome

Adverse events

Summary

This study is a single center, randomized, double-blind, placebo-controlled Phase I clinical
 study in a single dose escalation to evaluate its safety, tolerability, pharmacokinetics,
 pharmacodynamics, and immunogenicity of CM383 in male healthy subjects.

ICD-10 Classifications

Alzheimer disease
Alzheimer disease, unspecified
Other Alzheimer disease
Dementia in Alzheimer disease
Dementia in Alzheimer disease, unspecified

Data Source

ClinicalTrials.gov

NCT06412185

Non-Device Trial